Search results
Added:
1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
A new study has found that the novel oral GLP-1 receptor agonist, orforglipron, demonstrated superior glycaemic control compared to oral semaglutide in adults with type 2 diabetes (T2D). The findings come from the ACHIEVE-3 trial, a phase 3 study published in The Lancet.¹Mechanism of ActionOrforglipron is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-daily oral…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized…
View more
Added:
1 year ago
ESC Congress 2024 — Improved patient-level adherence to guideline recommendations on heart rhythm control through healthcare professional education in patients with atrial fibrillation.Investigator, Dr Dipak Kotecha (University of Birmingham, UK) joins us in London to share key findings from the STEEER-AF study (NCT04396418).This prospective, cluster-randomized international study compared two…
View more
Added:
2 months ago
Source:
Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension…
View more
Added:
1 year ago
Added:
2 years ago
EHRA 24 - In this video, investigator, Dr Giulio Falasconi (Humanitas Research Hospital, IT) joins us to discuss the findings from the QDOT-by-LAWT trial. This study included 162 patients with paroxysmal atrial fibrillation not responding to antiarrhythmic drugs. They were retrospectively enrolled and randomized on a 1:1 basis to the QDOT-by-LAWT study group, and the control group.Findings showed…
View more
Added:
8 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more
Added:
6 months ago
TCT 25 - Dr Raj Makkar (Cedars-Sinai Medical Center, US) joins us to discuss the findings on the EVOQUE Valve (Edwards Lifesciences) drawing from data in the STS/ACC Transcatheter Valve Therapy Registry.The study evaluated procedural success rates, in-hospital complications, and 30-day clinical outcomes in patients undergoing transcatheter tricuspid valve replacement for severe tricuspid…
View more
Added:
1 month ago
American College of Cardiology Congress 2026 – Dr Pam Taub (University of California San Diego, La Jolla, US) joins us to discuss results from the RECOVER-Autonomic platform trial (NCT06305806; Kanecia Obie Zimmerman), evaluating the impact of ivabradine on orthostatic intolerance, quality of life, and heart rate in post-COVID POTS.This randomised, placebo-controlled appendix trial enrolled 181…
View more